ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 938,73
0,08%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) Actualités

ARGX

Argen X (ARGX)

Argen X SE
De:
Trier par:
 Showing the most relevant articles for your search:EU:ARGX
DateHeureSourceTitreSymboleSociété
02/05/202407h00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
16/04/202407h00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
27/03/202407h00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
26/03/202421h00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
26/03/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
07/03/202422h01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
29/02/202407h00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
26/02/202407h00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
22/02/202407h00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
20/02/202407h00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
18/01/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/01/202407h00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
02/01/202407h00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceEU:ARGXArgen X SE
20/12/202307h00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusEU:ARGXArgen X SE
28/11/202307h00GlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
16/11/202313h40GlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisEU:ARGXArgen X SE
01/11/202307h00GlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsEU:ARGXArgen X SE
31/10/202307h00GlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
24/10/202307h00GlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023EU:ARGXArgen X SE
21/09/202307h00GlobeNewswire Inc.argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia GravisEU:ARGXArgen X SE
15/09/202307h00GlobeNewswire Inc.argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia GravisEU:ARGXArgen X SE
27/07/202307h00GlobeNewswire Inc.argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
24/07/202322h30GlobeNewswire Inc.argenx announces closing of global offeringEU:ARGXArgen X SE
20/07/202307h00GlobeNewswire Inc.argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023EU:ARGXArgen X SE
19/07/202323h58GlobeNewswire Inc.argenx announces full exercise of underwriters’ option to purchase additional ADSsEU:ARGXArgen X SE
19/07/202303h30GlobeNewswire Inc.argenx raises $1.1 billion in gross proceeds in a global offeringEU:ARGXArgen X SE
17/07/202322h01GlobeNewswire Inc.argenx announces launch of proposed global offeringEU:ARGXArgen X SE
17/07/202307h00GlobeNewswire Inc.argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
30/06/202315h39GlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in ChinaEU:ARGXArgen X SE
21/06/202300h12GlobeNewswire Inc.argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia GravisEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX

Dernières Valeurs Consultées

EU
ORA
Orange
EU
HO
Thales
EU
ML
Michelin
EU
PX1
CAC 40
COIN
BTCUSD
Bitcoin
EU
MC
Lvmh Moet Hennessy Louis...
EU
RNO
Renault
EU
LR
Legrand
USI
USTECH100
US Tech 100
EU
BNP
BNP Paribas
EU
EN
Bouygues
EU
BEL20
Bel 20
NYSE
MRK
Merck
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés